NCT Number: NCT03134586
Advanced Non-Invasive Diagnostics in Inflammatory Bowel Disease
The purpose of this study is to determine whether Non-invasive endoscopic procedures (pillcam colon capsule endoscopy, PCCE) and non-ionizing radiological modalities (MR enterocolonography, MREC and ultrasound, US) - offer a sufficiently high diagnostic validity in patients with suspected CD compared to the traditional invasive approach using ileocolonoscopy with biopsies as first line diagnostic modality
Looking for future studies?
Notify MeKey information
Conditions
Age range
15 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Sydvestjysk sygehus, Esbjerg, Denmark
About this study
This is a prospective, blinded, multicenter study of the diagnostic validity, inter-observer agreement, image quality and subjective experience of discomfort with PCCE, MREC and US in patients with suspected CD. Ileocolonoscopy serves as the diagnostic gold standard. Patients are recruited from 3 centers in the Region of Southern Denmark managing adult patients with inflammatory bowel diseases. Each patient goes through a standardized work-up including medical history, physical examination, C-reactive protein, fecal calprotectin, ileocolonoscopy, PCCE, MREC and US. All examinations are reviewed and described in a standardized fashion. The radiologists and physicians describing PCCE, MREC, and US are blinded to the findings at ileocolonoscopy and the other imaging modalities.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
General criterion
All of the following:
- Clinical suspicion of CD
- Age > 15 years
- Negative serologic markers for celiac disease, negative stool culture (or polymerase chain reaction) for pathogenic bacteria and a negative microscopy for intestinal parasites
- Fecal calprotectin > 50 mg/kg
- Signed informed consent
Clinical criterion Diarrhea and/or abdominal pain for more than 1 month (or repeated episodes of diarrhea and/or abdominal pain) associated with one or more of the following findings: (1) C-reactive protein (CRP) >5 mg/L, (2) thrombocytosis (> 400 x 109/L), anemia (hemoglobin < 7.0 mmol/L for women and < 8.0 mmol /L for men or a decrease > 0.5 mmol/L compared to the usual level), (3) prolonged fever (> 37.5 C for more than 2 weeks), (5) weight loss (≥ 3 kg or ≥ 5% compared to the normal body weight), (6) perianal abscess/fistula, or (7) a family history of inflammatory bowel disease.
Exclusion criteria
- Acute bowel obstruction
- Intake of NSAIDs or acetylsalicylic acid ≤ 4 weeks before inclusion except prophylactic treatment with low dose Aspirin (≤ 150 mg per day)
- Pregnancy or lactation
- Alcohol or drug abuse
- Known gastrointestinal disorder other than inflammatory bowel disease
- Renal failure defined by a plasma-creatinine above the normal reference range
- Claustrophobia, cardiac pacemaker or implanted magnetic foreign bodies that precludes MREC
- Interpreter required or inability to understand the oral and written information
- Colonoscopy contraindicated, performed within 3 months or unwillingness to go through colonoscopy
Treatment and study plan
Primary outcomes
-
Sensitivity and specificity of PCCE, MREC and US for the diagnosis of CD
Time frame: 36 months
Sensitivity and specificity of PCCE, MREC and US for the diagnosis of CD located in the terminal ileum and colon (per patient & per segment). Ileocolonoscopy serves as gold standard
-
Correlation of disease severity
Time frame: 36 months
Correlation of disease severity assessed with PCCE, MREC, US and ileocolonoscopy
-
Inter-observer agreement
Time frame: 36 months
Inter-observer agreement with PCCE, MREC, US and ileocolonoscopy
Secondary outcomes
-
Diagnostic yield of proximal CD
Time frame: 36 months
Diagnostic yield of PCCE, MREC and US for CD located proximal to the terminal ileum
-
Patients reported experience
Time frame: 36 months
Patients' subjective experience of discomfort during PCCE, MREC, US and ileocolonoscopy
-
Interobserver PCCE
Time frame: 36 months
Sensitivity and specificity of PCCE with different reading protocols
-
Utility of diffusion weighed magnetic resonance imaging (dw-MREC) and US Doppler flow
Time frame: 36 months
Utility of diffusion weighed magnetic resonance imaging (dw-MREC) and US Doppler flow (Limberg score): Sensitivity, specificity and correlation with endoscopic disease activity
Sponsors and collaborators
Lead sponsor
Esbjerg Hospital - University Hospital of Southern Denmark
Other
Collaborators
- Odense University Hospital
- Sygehus Lillebaelt
Registry information
Official study title
A Comparative Study of the Diagnostic Validity of Ultrasound, Magnetic Resonance Imaging and Capsule Endoscopy of Both the Small and Large Intestine in Suspected Crohn's Disease
Acronym: ANDI
Important dates
- Study start
- 2016
- Primary completion
- 2020
- Study completion
- 2020
- First posted
- May 1, 2017
- Registry last updated
- Nov 1, 2022
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT04673357
Crohn Disease, Digestive System Diseases
Wilmington, Delaware, United States
View Trial DetailsA Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
NCT05013905
Crohn Disease, Digestive System Diseases
Los Angeles, California, United States
View Trial DetailsIBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms
NCT06094608
Colitis, Colitis, Ulcerative
Ann Arbor, Michigan, United States
View Trial DetailsLoss of RESponse to Ustekinumab Treated by Dose Escalation
NCT04245215
Crohn Disease, Digestive System Diseases
Zaventem, Belgium
View Trial Details